Astoriom, a leader in scientific research and consumer product sample stability and biorepository storage, has expanded its sample management capabilities in the U.S. with the acquisition of Precision Stability Storage.

This acquisition marks a strategic expansion of Astoriom’s footprint in North America, strengthening its presence in high-growth regions for biopharmaceutical, biotechnology and medical technology innovation. With increased capacity, broader geographic coverage and faster access to GxP stability storage, Astoriom’s global customers will gain local access to reliable and compliant solutions to advance scientific discovery and product innovation.

Precision Stability Storage sites in Wilson (North Carolina), Fort Lauderdale (Florida) and Hopedale (Massachusetts) add to Astoriom’s extensive portfolio of global sample storage facilities. The facilities provide the highest standards of offsite stability storage, quality and compliance for products that require ICH-specified environmental conditions and storage of temperature-sensitive biological materials. This includes long-term and intermediate conditions (25°C/40% relative humidity (RH), 25°C/60%RH, 30°C/65%RH, 30°C/75%RH, 30°C/35%RH), accelerated storage (40°C/<25%RH, 40°C/75%RH), refrigerated and freezer storage conditions (2–8°C, -20°C, -80°C, -196°C) as well as ambient storage conditions (15–30°C). These capabilities will further enable Astoriom to secure, protect and preserve the viability and integrity of samples and products for its customers with enhanced geographic reach.

“Astoriom continues to expand into key markets, demonstrating both growth and long-term demand for our integrated services in the U.S.,” said Will Edwards, CEO, Astoriom. “This acquisition reinforces our unwavering commitment to providing global customers with local access to world-class stability storage facilities.”

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.